LAVAL, QC , Dec. 22, 2022 /CNW Telbec/ – Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC )  and its Canadian dermatology division, one of the largest prescription dermatology health care businesses in  Canada, today announced that its new topical prescription treatment for acne vulgaris, ARAZLO TM   (tazarotene cream, 0. 045% w/w), is now available to patients through the provincial public drug plans associated with Quebec , Ontario , Alberta plus Saskatchewan , as well as the federal government’s Non-Insured Health Benefits (NIHB) drug plan, which serves Canada’s Initial Nations and Inuit populations. 1

ARAZLO is the particular first tazarotene lotion therapy approved by Wellness Canada with regard to the topical ointment treatment of acne vulgaris in patients 10 years of age and older. 2 The listings by the four public drug plans are the first for ARAZLO in Canada , with others expected to follow as a result associated with the successful conclusion of listing negotiations with the pan-Canadian Pharmaceutical Alliance, representing the particular drug plans of the federal government and all provinces plus territories.

“We are very pleased to have achieved agreements for these first public drug plan entries in North america for ARAZLO, ” said Cees Heiman , Bausch Health, Senior Vice President, Europe and Canada .   “It is an important further step in helping to provide new treatment options for the approximately 5. 6 million Canadians who are impacted by acne. 4   We are very proud to have a large dermatology portfolio to help meet Canadians’ needs. ”

“While tazarotene is not the new retinoid, the vehicle in ARAZLO is a true innovation in topical technology and enhances the tolerability, and thus effectiveness, of this new product regarding acne patients, ” stated Dr. Jerry Tan , MD, FRCPC, of Windsor, Ontario , President from the Acne plus Rosacea Society of Europe , Adjunct Professor, Western University .

ARAZLO is the first tazarotene acne treatment available in a lotion formulated with PRISMATREX TM   technology (formulation with known hydrating and moisturizing effects, which may alleviate dryness associated with skin) 2   plus has been shown to offer a good tolerability profile. Retinoids like tazarotene are a core component of acne therapy. Providing the particular treatment in a lotion form helps limit the dryness and irritation that has historically been a barrier to the long-term use of tazarotene by individuals. 3

About Acne Vulgaris
Acne vulgaris (“vulgaris” means “common”) is the most common skin problem seen by doctors within Canada . It occurs when the pores of the skin become plugged with oil and pores and skin cells, often causing whiteheads, blackheads, pimples or cysts to appear on the face, forehead, chest, upper back and shoulders. Pimples affects about 5. 6 million Canadians, or nearly 20 per cent of the population plus causes emotional distress and can cause permanent scarring 2   or pigmentation changes. five   Acne affects about 90 per cent of adolescents and about 25 per cent associated with teens will still have pimples at age twenty five. 4

ARAZLO tazarotene lotion, 0. 045% w/w is a topical prescription indicated for the topical cream treatment of acne vulgaris. ARAZLO can be used on affected areas in sufferers 10 years and old. The safety and efficacy of ARAZLO in children below the particular age of 10 years offers not already been established. two

About Bausch Health
Bausch Wellness Companies Inc. (NYSE/TSX: BHC ) is a global diversified pharmaceutical company whose mission is to improve people’s lives with our health care products.   We develop, manufacture and market a range of items primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals  and eye health, via our controlling interest in Bausch + Lomb. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit   and connect with us on  Twitter   and  LinkedIn .

Bausch Health, Canada Incorporation. ‘s   prescription treatment portfolio is focused on dermatology -, gastrointestinal and cardio-metabolic conditions. Bausch Health also has two manufacturing facilities for prescription pharmaceuticals inside Canada , in Laval, Quebec , and Steinbach, Manitoba . More information can be found at the Company’s website at .


1 . Quebec : assessed Nov. 18, 2022
Ontario :  

Alberta :  

Saskatchewan :  

NIHB :  

2 . ARAZLO (Tazarotene Lotion) Product Monograph, July 7, 2021 .

a few. “Targeted Topical Delivery associated with Retinoids in the Management of Acne Vulgaris: Current Formulations and Novel Delivery Systems. ” Pharmaceutics. Gemma Latter et al, October 2019 , , accessed Nov. one, 2022 .

4. Canadian Dermatology Association, Acne, Quick Facts,,adults%20ages%2020%20to%2040 , utilized Nov. 1, 2022 .

5. “What to Know about Hyperpigmentation Acne. inch Medical News Today , Jessica Caporuscio , April 28 , 2021, , accessed Nov. 1, 2022 .

SOURCE Bausch Wellness

For further information: Investor Contact: Christina Cheng, [email protected] , (514) 856-3855, (877) 281-6642 (toll free); Media Get in touch with: Kevin Wiggins, [email protected] , (908) 927-1198

Leave a Reply

Your email address will not be published. Required fields are marked *